NCT07519590Completed
One-Time Complete Revascularization Versus Staged PCI in MVD During Pharmaco-Invasive STEMI Strategy
One Time Complete Revascularization Versus Staged PCI in Multivessel Coronary Artery Disease During Pharmaco Invasive STEMI Strategy
Source: ClinicalTrials.gov · Last updated 9 Apr 2026
Brief summary (registry, in English)
This study compares two treatment strategies in patients with ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD) undergoing a pharmaco-invasive approach after successful fibrinolysis. The study evaluates whether one-time complete revascularization, in which the culprit and significant non-culprit lesions are treated during the same percutaneous coronary intervention (PCI) session, is better than a staged strategy, in which non-culprit lesions are treated in a separate percutaneous coronary intervention (PCI) procedure within 1 month. The hypothesis is that one-time complete revascularization may reduce hospitalization time, cost, and recurrent ischemic symptoms without increasing short-term complications. Participants are adults with acute ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD) who had successful fibrinolysis followed by coronary angiography and percutaneous coronary intervention (PCI). Outcomes include total hospitalization time, total expenses, contrast-induced nephropathy (CIN) within 72 hours, and major adverse cardiovascular events (MACE) during 3 months of follow-up.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 112 (actual)
- First submitted
- 2 Apr 2026
- Start date
- 30 Apr 2023
- Primary completion date
- 30 Jul 2024
- Lead sponsor
- Tanta University
- Diseases
- Coronary artery disease
- NCT number
- NCT07519590
What you commit to
- Study type: Interventional
- Participants enrolled: 112
- From 30 Apr 2023 to the primary completion date, 30 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Single-vessel coronary artery disease treated with a pharmaco-invasive strategy.
- Prior cardiac surgery.
Other illness
- Stent thrombosis.
- Severe valvular heart disease.
- Congenital heart disease.
- Severe hepatic impairment.
- Severe renal impairment.
Other
- Primary percutaneous coronary intervention.
- Unsuccessful fibrinolysis requiring rescue percutaneous coronary intervention.
- Candidacy for coronary artery bypass grafting after angiography.
- Failed complete revascularization.
- Cardiogenic shock.
- Chronic total occlusion.
- Planned percutaneous transluminal coronary angioplasty to a non-culprit lesion in a vessel smaller than 2.5 millimeters with more than 70 percent stenosis.
- Pregnancy.
Who the study is looking for
- Adults older than 18 years.
- Acute ST-elevation myocardial infarction treated with a pharmaco-invasive strategy.
- Successful fibrinolysis followed by coronary angiography and percutaneous coronary intervention.
- Multivessel coronary artery disease.
- Ability to provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Helwan University Hospital Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.